Img header logo

ESG Data

アンカーリンク用

Regarding the data for FY2021 marked with , we have received independent assurance in our SUSTAINABILITY DATA 2022 (PDF version) so as to bolster the reliability of the information. For details, please see the “Independent Practitioner's Assurance.”Governance Data

ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Governance Data

Corporate Governance
Item Scope Unit FY2017 FY2018 FY2019 FY2020 FY2021
Board structure Directors (Total) Non-consolidated Persons 7 8 8 8 8
Independent outside directors Non-consolidated Persons 2 3 3 3 3
Female directors Non-consolidated Persons 0 0 0 1 1
Board of Auditors structure Auditors (Total) Non-consolidated Persons 4 4 4 4 4
Independent outside auditors Non-consolidated Persons 2 2 2 2 2
Female auditors Non-consolidated Persons 1 1 1 1 1
Director Remuneration Total Non-consolidated Million yen 336 360 368 384 428
President, Representative Director, and Chief Executive Officer Non-consolidated Million yen - 114 116 126 125
Auditor Remuneration Total Non-consolidated Million yen 76 77 78 83 85
Number of Board of Directors meetings Non-consolidated Times 13 13 13 13 15
Number of Board of Auditors meetings Non-consolidated Times 13 14 14 19 16
Board attendance rate(directors) Non-consolidated % 100 100 100 98.6 100
Board attendance rate(auditors) Non-consolidated % - 100 92.3*1 100 100
  • The attendance rate of Audit & Supervisory Board Members excluding the Audit & Supervisory Board Member who resigned due to illness on March 27, 2020 was 100%.
Compliance
Item Scope Unit FY2017 FY2018 FY2019 FY2020 FY2021
Compliance training attendance rate Non-consolidated % - 100 100 100 100
Number of reports Discrimination and harassment related Non-consolidated Incidents - - 22 15 29
Personnel and labor management related Non-consolidated Incidents - - 2 1 2
Others Non-consolidated Incidents - - 44 6 29
Total Non-consolidated Incidents - 44 68 22 60
Number of compliance violations(Disciplinary action cases) Discrimination and harassment related Non-consolidated Incidents - - 3 1 0
Personnel and labor management related Non-consolidated Incidents - - 0 0 1
Bribery cases Non-consolidated Incidents 0 0 0 1 0
Others Non-consolidated Incidents - - 6 0 10
Total Non-consolidated Incidents - 5 9 2 11
Costs for legal violations Non-consolidated Million yen - - - 0 0
Number of facilitation payments Non-consolidated Incidents 0 0 0 0 0
ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Social Data

ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Environmental Data

GHG emissionsThe scope of environmental data is non-consolidated basis.
Since the figures in the table are rounded, the breakdown totals may not always coincide with the overall totals.
Item Scope Unit FY2017 FY2018 FY2019 FY2020 FY2021
GHG emissions (Market-basis) Production and research sites kt-CO2 27.2 26.1 25.2 24.1 21.8
Headquarters and other Sites in Japan (including tenant locations) kt-CO2 2.6 2.4 2.1 2.0 1.7
Total kt-CO2 29.8 28.5 27.3 26.1 23.6
GHG emissions scope breakdown (Market-basis) Scope 1 (Breakdown by GHG type) Energy-derived All operation sites kt-CO2 8.5 9.0 9.7 10.0 9.8
Non-energy-derived
(HFCs,  HCFCs)
0.2 0.5 0.4 0.1 0.03
Total 8.7 9.5 10.1 10.1 9.8
Scope 2 All operation sites kt-CO2 21.1 19.1 17.1 15.9 13.7
Amount of CO2 offset due to voluntary credit(Carbon-neutral city gas purchased) Joto Pharmaceutical Product Development Center, Tsukuba Research Institute kt-CO2 - - - - 0.6
GHG emissions after offset All operation sites kt-CO2 - - - - 23.0
  • Sites where data were collected: Fujiyama Plant, Yamaguchi Plant (added from FY2018), Joto Pharmaceutical Product Development Center, Minase Research Institute, Fukui Research Institute, Tsukuba Research Institute, Head Office, sales offices and other offices, etc.
    GHG emissions are calculated using the following formula.
    GHG emissions = Purchased electricity × Adjusted emission factor published by electric power company + Σ (Fuel consumption × Unit calorific value × Carbon emission factor × 44/12) + Σ (Fluorocarbon leakage amount × Global warming potential)
    The amount of green electric power certified under the Green Energy Certificate and , the amount of renewable energy certified under the J-Credit Scheme and the Non-Fossil Fuel Certificate quota are deducted
     
GHG emissions in the value chain (Scope3)
Category Calculation method Notes Scope Unit FY2017 FY2018 FY2019 FY2020 FY2021
Cat1 Purchased goods and services GHG emissions (scope  1,2) volume of our major suppliers of raw materials and materials (accounting for 80% or more of our raw materials or materials purchase costs) multiplied by the ratio of the sales to ONO out of the total sales of the supplier. Ratios for other business suppliers are assumed to follow the same trend as for major suppliers, and are calculated using the ratio of GHG emissions to the transaction amount at major suppliers. ·This category is closely associated with our business activities since active pharmaceutical ingredients for manufacturing of drugs, intermediate products and research reagents are included.
·Covers production and research sites
·Figures for FY2021 are not calculated because our major suppliers had not published their CSR reports at the time of calculation.
All operation sites kt-CO2 8.5 8.1 11.5 12.7 -
Cat2 Capital goods Amount of capital goods treated as fixed assets (reinforcement of facilities/maintenance investment) excluding land, multiplied by factor Calculated based on capital goods treated as fixed assets. The fixed assets used in this calculation are essential for business activities. kt-CO2 52.6 60.4 26.9 25.8 26.4
Cat3 Fuel- and energy-related activities not included in scope 1 or scope 2 Amount of non-renewable electricity purchased, multiplied by emission factor - kt-CO2 1.5 1.5 2.8 2.7 2.4
Cat4 Upstream transportation and distribution Transport data on deliveries from our production sites and distribution centers to destinations, multiplied by emission factor - kt-CO2 0.1 0.1 0.1 0.1 0.1
Cat5 Waste generated in operations Weight of each type of industrial waste generated, multiplied by emission factor - kt-CO2 0.3 0.3 0.3 0.3 0.3
Cat6 Business travel Business travel costs, multiplied by emission factor Covers travels by airplane or Shinkansen bullet train kt-CO2 2.5 2.3 4.0 0.4 0.5
Cat7 Employee commuting Commuting costs, multiplied by emission factor The commuting costs includes the amount for commuting by car from 2021 kt-CO2 0.4 0.4 0.5 0.4 0.7
Cat8 Upstream leased assets Fuel consumption used in leased vehicles, multiplied by emission factor - kt-CO2 3.5 3.3 2.9 2.0 2.1
Cat9 Downstream transportation and distribution GHG emissions stated in CSR reports on our major pharmaceutical wholesalers, multiplied by percentage of our net sales included in all net sales of major pharmaceutical wholesalers ·Transportation and distribution are important business activities to control distribution of and to ensure stable supply of drugs.
· Figures for FY2021 are not calculated because our major pharmaceutical wholesalers had not published their CSR reports at the time of calculation.
kt-CO2 5.3 5.3 4.9 5.0 -
Cat10 Processing of sold products - We make only finished products kt-CO2 Not relevant Not relevant Not relevant Not relevant Not relevant
Cat11 Use of sold products - No energy is consumed during the use of ONO products Not relevant Not relevant Not relevant Not relevant Not relevant
Cat12 End-of-life treatment of sold products Weight of each type of our product container or packaging disposed of as waste, multiplied by emission factor - kt-CO2 0.1 0.2 0.2 0.2 0.1
Cat13 Downstream leased assets Floor space of asset (building) owned and rented out categorized by use, multiplied by emission factor - kt-CO2 0.3 0.3 0.3 0.3 0.3
Cat14 Franchises - ONO does not operate franchises kt-CO2 Not relevant Not relevant Not relevant Not relevant Not relevant
Cat15 Investments - There is no investment involving large amounts of greenhouse gas emissions. kt-CO2 Not relevant Not relevant Not relevant Not relevant Not relevant
Total kt-CO2 75.1 82.2 54.4 49.8 -
  • Categories 1 and 9 of scope 3 and their total for FY2021 are not calculated because our major suppliers and pharmaceutical wholesalers had not published their CSR reports at the time of calculation.
  • The emission factors used for calculation are figures stated in the "Emission Factor Database on Accounting for Greenhouse Gas Emissions throughout the Supply Chain (FY2017, Ver. 2.4; FY2018, Ver. 2.6; FY2019, Ver. 3.0; FY2020, Ver. 3.1; FY2021, Ver. 3.2)," published by the Ministry of the Environment, Government of Japan.
Energy consumption
Item Scope Unit FY2017 FY2018 FY2019 FY2020 FY2021
Energy consumption Production and research sites MWh 83,906.2 88,423.4 96,369.2 98,025.2 94,433.7
Headquarters and other Japan offices/sites (including tenant locations) MWh 5,256.9 5,340.4 5,236.4 5,179.1 5,004.3
Total MWh 89,163.1 93,763.8 101,605.6 103,204.3 99,438.0
Share of renewable energy in total electricity consumption Electricity consumption Private power generation (renewable) (solar power generation) All operation sites MWh 55.3 65.0 63.0 63.3 61.9
Purchased electricity (renewable) (Non-fossil fuel) MWh - - 1,278.0 1,954.7 2,040.0
Private power generation (non-renewable) MWh 7,927.0 8,856.2 8,185.3 8,566.3 8,283.7
Purchased electricity (non-renewable) MWh 41,820.1 43,734.4 46,351.7 45,232.2 42,833.5
Total
(total electricity consumption)
MWh 49,802.4 52,655.5 55,878.0 55,816.5 53,219.2
Amount of credits purchased Solar power generation MWh - - 2,427.0 4,946.6 3,937.9
Biomass power generation MWh - 2,900.0 2,460.9 386.2 3,000.0
Renewable energy usage*5 MWh 55.3 2,965.0 6,228.9 7,350.7 9,039.9
Renewable energy usage rate (renewable energy usage / total electricity consumption) 0.1 5.6 11.1 13.2 17.0
  • Sites where data were collected: Fujiyama Plant, Yamaguchi Plant (added from FY2018), Joto Pharmaceutical Product Development Center, Minase Research Institute, Fukui Research Institute, Tsukuba Research Institute, Head Office, sales offices and other offices, etc.
  • Renewable energy usage = Private power generation (renewable) + Purchased electricity (renewable) + Amount of credits purchased
Water intake and wastewater volume by site (unit: 1,000 m3)
Site name River in the area Wastewater drainage destination FY2017 FY2018 FY2019 FY2020 FY2021
Water intake volume Wastewater volume Water intake volume Wastewater volume Water intake volume Wastewater volume Water intake volume Wastewater volume Water intake volume Wastewater volume
Fujiyama Plant Fuji River River 205.6 148.6 240.2 178.4 185.0 145.1 157.8 125.0 138.7 110.2
Joto Pharmaceutical Product Development Center Yodo River Sewer 5.5 5.5 6.0 6.0 5.1 5.1 4.6 4.6 3.9 3.9
Yamaguchi Plant Fushino River River - - 8.2 8.2 18.1 18.1 18.6 17.7 21.6 20.0
Minase Research Institute Yodo River Sewer 51.3 51.3 41.2 41.2 39.1 39.1 33.7 33.7 31.5 31.5
Fukui Research Institute Kuzuryu River Sewer 38.7 5.2 31.3 5.0 27.3 5.7 13.7 2.6 6.6 1.9
Tsukuba Research Institute Lake Kasumigaura Sewer 8.1 8.1 6.0 6.0 7.1 7.1 7.2 7.2 7.0 7.0
Head Office and other sites in Japan (including tenant locations) Rivers/lake in the areas where major business sites are located*6 Sewer 15.9 15.9 15.1 15.1 15.0 15.0 10.0 10.0 10.0 10.0
Total 325.1 234.6 348.0 259.9 296.7 235.2 245.6 200.8 219.4 184.5
  • Sites where data were collected: Fujiyama Plant, Yamaguchi Plant (added from FY2018), Joto Pharmaceutical Product Development Center, Minase Research Institute, Fukui Research Institute, Tsukuba Research Institute, Head Office, sales offices and other offices, etc.
  • Basins of major offices: Toyohira River, Okura River, Arakawa River, Sakawa River, Kiso River, Lake Biwa, Yodo River, Ota River, Yoshino River, Naka River
Activities to reduce water consumption (rate of recycled water)
Item Scope Unit FY2017 FY2018 FY2019 FY2020 FY2021
Percentage of reused water Production and research sites % 5.9 4.8 5.5 2.0 1.6
Waste Management, and Recycling Containers and Product Packaging
Item Scope Unit FY2017 FY2018 FY2019 FY2020 FY2021
Industrial waste Waste generated Production and research sites, etc. t 719.1 446.4 430.8 502.7 479.1
Special management industrial waste (hazardous waste)*7 Production and research sites, etc. t 137.0 145.6 161.9 171.2 170.3
final landfill disposal Production and research sites, etc. t 7.4 0.4 0.2 1.1 0.2
final landfill disposal rate Production and research sites, etc. % 1.0 0.1 0.1 0.2 0.04
final landfill disposal (Non-industrial waste is included) Production and research sites t 18.0 9.4 6.7 5.9 5.3
Container and packaging usage Plastic Production t 164.7 171.7 162.8 161.5 147.0
Paper Production t 192.0 202.7 200.9 198.1 175.6
Glass (colorless) Production t 0.0 0.0 0.0 0.0 0.0
Glass (brown) Production t 0.3 0.3 0.3 0.2 0.2
Obligatory recycling amount Plastic Production t 34.7 35.5 31.2 35.1 36.6
Paper Production t 1.6 1.6 1.5 1.4 1.3
Glass (colorless) Production t 0.0 0.0 0.0 0.0 0.0
Glass (brown) Production t 0.0 0.0 0.0 0.0 0.0
Commissioning fee paid for recycling Production 1,000 yen 1,723.0 1,650.0 1,546.0 1,814.0 1,958.0
  • Sites where data were collected: Fujiyama Plant, Yamaguchi Plant (added from FY2018), Joto Pharmaceutical Product Development Center, Minase Research Institute, Fukui Research Institute, Tsukuba Research Institute /Logistics Center (added from FY2021)
    The final industrial landfill disposal volume of industrial waste in FY2017 was calculated with inclusion of the amount of waste (5.8 tons) from the renovation of the Joto Pharmaceutical Product Development Center.
  • Special management industrial waste (hazardous waste) is defined under the Waste Management and Public Cleansing Law as waste that has properties of explosiveness, toxicity, infectiousness, and/or possibly causing damage to human health or the living environment. We strive to manage this type of waste properly.
Prevention of Air Pollution and Water Pollution
Item Scope Unit FY2017 FY2018 FY2019 FY2020 FY2021
Emissions into the air SOx Production and research sites t 0.0 0.0 0.0 0.0 0.0
NOx Production and research sites t 7.8 8.4 8.1 8.1 8.3
Particulate matter Production and research sites t 0.3 0.3 0.3 0.3 0.3
PRTR substance Production and research sites t 0.2 0.2 0.1 0.4 0.3
Emissions into water Wastewater Production and research sites 1,000m3 218.7 244.8 220.2 190.8 174.5
BOD Production and research sites t 2.2 1.3 1.3 1.2 1.3
PRTR substance Production and research sites t 0.0 0.0 0.0 0.0 0.0
Management of Chemicals (PRTR substances)
Item Scope Unit FY2017 FY2018 FY2019 FY2020 FY2021
Amount handled by the notified facilities Acetonitrile Production and research sites t 9.0 7.2 8.5 10.4 9.3
Normal-hexane Production and research sites t 3.0 2.8 3.0 2.6 2.3
Total Production and research sites t 12.0 10.0 11.5 13.0 11.6
Dioxins Production and research sites mg-TEQ - - - - -
Notified release (into the air) Acetonitrile Production and research sites t 0.4 0.2 0.1 0.3 0.3
Normal-hexane Production and research sites t 0.0 0.0 0.0 0.0 0.0
Total Production and research sites t 0.4 0.2 0.1 0.3 0.3
Dioxins Production and research sites mg-TEQ - - - - -
Notified release (into public waters) Acetonitrile Production and research sites t 0.0 0.0 0.0 0.0 0.0
Normal-hexane Production and research sites t 0.0 0.0 0.0 0.0 0.0
Total Production and research sites t 0.0 0.0 0.0 0.0 0.0
Dioxins Production and research sites mg-TEQ - - - - -
Notified transfer (contained in waste) Acetonitrile Production and research sites t 8.8 6.9 8.4 10.1 8.9
Normal-hexane Production and research sites t 3.0 2.8 3.0 2.6 2.3
Total Production and research sites t 11.8 9.8 11.3 12.7 11.3
Dioxins Production and research sites mg-TEQ 0.0 - - - -
Notified transfer (Into public sewage) Acetonitrile Production and research sites t 0.0 0.0 0.0 0.0 0.0
Normal-hexane Production and research sites t 0.0 0.0 0.0 0.0 0.0
Total Production and research sites t 0.0 0.0 0.0 0.0 0.0
Dioxins Production and research sites mg-TEQ - - - - -
Notified release and transfer (total) Acetonitrile Production and research sites t 9.0 7.2 8.5 10.4 9.3
Normal-hexane Production and research sites t 3.0 2.8 3.0 2.6 2.3
Total Production and research sites t 12.0 10.0 11.5 13.0 11.6
Dioxins Production and research sites mg-TEQ - - - - -
Management of Chemicals (PCB)
Item Scope Unit FY2017 FY2018 FY2019 FY2020 FY2021
Joto Pharmaceutical Product Development Center In use or stored Production and research sites Stand 552 552 0 0 0
Minase Research Institute In use or stored Production and research sites Stand 0 0 0 0 2
  • In FY2019, the Joto Pharmaceutical Product Development Center brought in 552 units of equipment to the Japan Environmental Storage and Safety Corporation, a processing facility, and disposed of them appropriately. One condenser was found at the Joto Pharmaceutical Product Development Center in FY2020, but it was properly disposed of in FY2020. The Minase Research Institute found that two transformers in use fell within the scope of the “Act on Special Measures concerning Promotion of Proper Treatment of PCB Wastes” in 2021, and submitted a report on the storage and disposal of waste of polychlorinated biphenyls to the Osaka municipal government.
Environmental Management
Item Scope Unit FY2017 FY2018 FY2019 FY2020 FY2021
Status of acquisition of ISO 14001 certification for sites Production site 100% 100% 100% 100% 100%
  • Scope of ISO 14001 certification at production sites.
Environmental Violations
Item Scope Unit FY2017 FY2018 FY2019 FY2020 FY2021
Number of breaches of legal obligation/regulatory violations All operation sites Cases 0 0 0 0 0
Amount of breach-/violation-related fines All operation sites Million yen 0 0 0 0 0
Environmental liabilities as of fiscal year-end All operation sites Million yen 0 0 0 0 0
  • Breach/violation cases with fines of USD 10,000 or more
    The above includes violations related to air and soil pollution, noise, vibration, and water quality.
ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Social Contribution Activities Data

Initiatives for medical advancement
Item Scope Unit FY2017 FY2018 FY2019 FY2020 FY2021
Osamu Hayaishi Memorial Award - Persons 1 1 1 1 1
Recipients of theresearch grant - Persons 12 12 12 12 12
Recipients of theresearch scholarship grant(40 years old and below) - Persons 16 16 16 16 16
Recipients of the Osamu Hayaishi Memorial Scholarship for Study Abroad - Persons 8 8 8 8 8
ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system